• Home
  • About
  • All Companies
    • Recent
    • Summary Lists
  • Contact

iTolerance

  • September 3, 2021
  • New Biotech Startups

Founded in 2020, iTolerance is regenerative medicine company developing a potential cure for Type 1 Diabetes that eliminates the need for chronic immunosuppression of patients.

The company’s lead program, ITOL-101, is an adjunct therapy with pancreatic islet cell implant currently in development for the treatment of or as a potential breakthrough cure for Type 1 Diabetes. As an adjunct therapy with pancreatic islet cells, the company says that ITOL-101 creates a durable, localized immune tolerance that has the potential to protect implanted islet cells from rejection by the body’s own immune system. This localized immune acceptance potentially eliminates the need for sustained immunosuppressants and allows for localized remodeling and functional engraftment. iTolerance reports that ITOL-101 has demonstrated compelling efficacy in non-human primate studies. The company plans to advance ITOL-101 towards an IND and first-in-man study.

In addition to ITOL-101, iTolerance is advancing its regenerative cell therapy platform to fuel a ‘robust’ pipeline addressing other high-value indications.

The company’s technology was originally developed by the University of Louisville and the Georgia Institute of Technology, with support from the National Institutes of Health and JDRF.


Subscribe for alerts on new companies featured on Startups.Bio


May 24, 2022Aulos Bioscience
Aulos Bioscience aims to revolutionize cancer patient care through the development of pioneering Interleukin-2 therapeutics for the treatment of solid tumor cancers. Interleukin-2 or IL-2 …
May 18, 2022Code Bio
Code Bio is using its novel targeted non-viral delivery platform to develop genetic medicines for serious and life-threatening diseases such as Type 1 Diabetes and …
May 9, 2022Muna Therapeutics
Muna Therapeutics aims to preserve brain function and enhance resilience to neurodegenerative diseases.  The company engages in the discovery and development of novel therapies that …
April 27, 2022Glyphic Biotechnologies
Glyphic Biotechnologies is an MIT spin-out aiming to accelerate the critical but slow step of sequencing new proteins, potentially cutting drug development times down by …
April 24, 2022ImmuneID 
ImmuneID is a precision immunology company that has developed a genome-wide, high-throughput platform to provide an understanding of individual immune responses. ImmuneID's aiSPIRE platform screens billions of …
April 15, 2022Flare Therapeutics
Flare uses a “switch-site based drug discovery approach” to develop a pipeline of therapeutic programs that target pivotal cancer drivers such as transcription factor dysregulation …

Tags:

© Copyright 2022. Startups.Bio, powered by VentureRadar.